The epitopes of MSLN peptides, specifically tailored for cytotoxic T lymphocytes (CTLs) clones, shared sequences previously demonstrated to exert an anti-tumor effect against MSLN-expressing malignant pleural mesothelioma [56] and pancreatic cancer cells [57]. This evidence concerns the gene MSLN and malignant pleural mesothelioma.